Skip to main content
SpringerLink
Log in

Cannabis Use Disorder and Its Treatment

  • Chapter
  • First Online:
Textbook of Addiction Treatment

  • 353 Accesses

Abstract

Scientific advances and clinical epidemiology provide clear evidence of cannabis’ potential for addiction and adverse psychosocial and health consequences, yet skepticism about its addictive potential remains, and perceived risk of its potential for harm continues to decrease. Indeed, treatment seeking for cannabis use disorder (CUD) comprises a substantial proportion of all substance use treatment admissions. This chapter is focused on cannabis’ potential for misuse and addiction and reviews what is known about behavioral and pharmacological interventions for cannabis use reduction or cessation. Behavioral treatments, brief interventions, and digital health interventions have demonstrated efficacy, although there remains much room for continued improvement in outcomes. Unfortunately, a growing body of research has yet to identify an effective pharmacotherapy, and no medications are currently approved by the FDA for treating CUD. Continued efforts to identify and increase access to effective interventions for misuse and CUD are imperative to the public health considering the loosening of cannabis laws for both therapeutic and recreational use, the burgeoning of cannabis industry, and societal and cultural trends toward acceptance of cannabis use. The field will continue to benefit from efforts to develop innovative treatments that leverage scientific and technological advances and that better tailor interventions to individuals or subgroups of cannabis users.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction. 2009;104(4):518–32. doi: ADD2504 [pii] https://doi.org/10.1111/j.1360-0443.2009.02504.x.

    Article  Google Scholar 

  2. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. https://doi.org/10.1001/jamapsychiatry.2013.3947.

    Article  CAS  Google Scholar 

  3. APA. Diagnostic and statistical manual of mental disorders. Arlington: American Psychiatric Association; 2013.

    Google Scholar 

  4. Bernstein E, Edwards E, Dorfman D, Heeren T, Bliss C, Bernstein J. Screening and brief intervention to reduce marijuana use among youth and young adults in a pediatric emergency department. Acad Emerg Med. 2009;16(11):1174–85. https://doi.org/10.1111/j.1553-2712.2009.00490.x.

    Article  Google Scholar 

  5. Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M. Probability and predictors of treatment-seeking for substance use disorders in the U.S. Drug Alcohol Depend. 2015;149:136–44.

    Article  Google Scholar 

  6. Borodovsky JT, Budney AJ. Cannabis regulatory science: risk–benefit considerations for mental disorders. Int Rev Psychiatry. 2018;30:1–20. https://doi.org/10.1080/09540261.2018.1454406.

    Article  Google Scholar 

  7. Boumparis N, Loheide-Niesmann L, Blankers M, Ebert DD, Korf D, Schaub MP, et al. Short- and long-term effects of digital prevention and treatment interventions for cannabis use reduction: a systematic review and meta-analysis. Drug Alcohol Depend. 2019;200:82–94. https://doi.org/10.1016/j.drugalcdep.2019.03.016.

    Article  Google Scholar 

  8. Brezing CA, Choi CJ, Pavlicova M, Brooks D, Mahony AL, Mariani JJ, Levin FR. **Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict. 2018;27(2):101–7. https://doi.org/10.1111/ajad.12660.

    Article  Google Scholar 

  9. Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018;43(1):173–94. https://doi.org/10.1038/npp.2017.212.

    Article  CAS  Google Scholar 

  10. Brunette MF, Dawson R, O’Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011;7(1–2):50–63.

    Article  Google Scholar 

  11. Budney AJ, Hughes JR, Moore BA, Vandrey RG. A review of the validity and significance of the cannabis withdrawal syndrome. Am J Psychiatry. 2004;161(11):1967–77.

    Article  Google Scholar 

  12. Budney AJ, Lile JA. Moving beyond the cannabis controversy into the world of the cannabinoids. Int Rev Psychiatry. 2009;21(2):91–5. doi: 910429540 [pii] https://doi.org/10.1080/09540260902782729.

    Article  Google Scholar 

  13. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112(3):393–402.

    Article  Google Scholar 

  14. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4–16.

    Article  Google Scholar 

  15. Budney AJ, Stanger C, Tilford JM, Scherer EB, Brown PC, Li Z, et al. Computer-assisted behavioral therapy and contingency management for cannabis use disorder. Psychol Addict Behav. 2015;29(3):501–11. https://doi.org/10.1037/adb0000078.

    Article  Google Scholar 

  16. Campbell CI, Bahorik AL, Kline-Simon AH, Satre DD. The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend. 2017;178:170–5.

    Article  Google Scholar 

  17. Chou SP, Goldstein RB, Smith SM, Huang B, Ruan WJ, Zhang H, et al. The epidemiology of DSM-5 nicotine use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. J Clin Psychiatry. 2016;77(10):1404–12. https://doi.org/10.4088/JCP.15m10114.

    Article  Google Scholar 

  18. Corsi DJ, Hsu H, Weiss D, Fell DB, Walker M. Trends and correlates of cannabis use in pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public Health. 2019;110(1):76–84. https://doi.org/10.17269/s41997-018-0148-0.

    Article  Google Scholar 

  19. D’Amico EJ, Miles JN, Stern SA, Meredith LS. Brief motivational interviewing for teens at risk of substance use consequences: a randomized pilot study in a primary care clinic. J Subst Abus Treat. 2008;35(1):53–61. https://doi.org/10.1016/j.jsat.2007.08.008.

    Article  Google Scholar 

  20. D’Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45. https://doi.org/10.1016/S2215-0366(18)30427-9.

    Article  Google Scholar 

  21. de Gee EA, Verdurmen JE, Bransen E, de Jonge JM, Schippers GM. A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users. J Subst Abus Treat. 2014;47(3):181–8. https://doi.org/10.1016/j.jsat.2014.05.001.

    Article  Google Scholar 

  22. Degenhardt L, Ferrari AJ, Calabria B, Hall W, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10):e76635. https://doi.org/10.1371/journal.pone.0076635.

    Article  CAS  Google Scholar 

  23. Dennis ML, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, et al. The cannabis youth treatment (CYT) study: main findings from two randomized trials. J Subst Abus Treat. 2004;27:197–213. https://doi.org/10.1016/j.jsat.2003.09.005.

    Article  Google Scholar 

  24. Dennis ML, Scott CK, Funk RR, Nicholson L. A pilot study to examine the feasibility and potential effectiveness of using smartphones to provide recovery support for adolescents. Subst Abus. 2015;36(4):486–92. https://doi.org/10.1080/08897077.2014.970323.

    Article  Google Scholar 

  25. ElSohly. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539–48.

    Article  CAS  Google Scholar 

  26. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81:263–84.

    Article  CAS  Google Scholar 

  27. Gates P, Copeland J, Swift W, Martin G. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev. 2012;31(3):311–9. https://doi.org/10.1111/j.1465-3362.2011.00313.x.

    Article  Google Scholar 

  28. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;(5). https://doi.org/10.1002/14651858.CD005336.pub4.

  29. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12. https://doi.org/10.1176/appi.ajp.2012.12010055.

    Article  Google Scholar 

  30. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249–57. https://doi.org/10.1016/j.drugalcdep.2017.04.020.

    Article  CAS  Google Scholar 

  31. Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 2016;73(3):300–1. https://doi.org/10.1001/jamapsychiatry.2015.3111.

    Article  Google Scholar 

  32. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Factors influencing marijuana self-administration by humans. Behav Pharmacol. 1997;8:101–12.

    Article  CAS  Google Scholar 

  33. Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, et al. Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Addict Biol. 2019;24(4):707–16. https://doi.org/10.1111/adb.12621.

    Article  CAS  Google Scholar 

  34. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015;40(11):2489–98. https://doi.org/10.1038/npp.2015.108.

    Article  CAS  Google Scholar 

  35. Hartzler B, Lyon AR, Walker DD, Matthews L, King KM, McCollister KE. Implementing the teen marijuana check-up in schools—a study protocol. Implement Sci. 2017;12(1):103. https://doi.org/10.1186/s13012-017-0633-5.

    Article  Google Scholar 

  36. Hasin D, Saha T, Kerridge B, Goldstein R, Chou P, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235–42. https://doi.org/10.1001/jamapsychiatry.2015.1858.

    Article  Google Scholar 

  37. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016;173(6):588–99. https://doi.org/10.1176/appi.ajp.2015.15070907.

    Article  Google Scholar 

  38. Hoch E, Preuss UW, Ferri M, Simon R. Digital interventions for problematic cannabis users in non-clinical settings: findings from a systematic review and meta-analysis. Eur Addict Res. 2016;22(5):233–42. https://doi.org/10.1159/000445716.

    Article  Google Scholar 

  39. Hogue A, Henderson CE, Ozechowski TJ, Robbins MS. Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007-2013. J Clin Child Adolesc Psychol. 2014;43(5):695–720. https://doi.org/10.1080/15374416.2014.915550.

    Article  Google Scholar 

  40. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-sective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58:322–8.

    Article  CAS  Google Scholar 

  41. Kay-Lambkin FJ, Baker AL, Kelly B, Lewin TJ. Clinician-assisted computerised versus therapist-delivered treatment for depressive and addictive disorders: a randomised controlled trial. Med J Aust. 2011;195(3):S44–50.

    Google Scholar 

  42. Kay-Lambkin FJ, Simpson AL, Bowman J, Childs S. Dissemination of a computer-based psychological treatment in a drug and alcohol clinical service: an observational study. Addict Sci Clin Pract. 2014;9:15. https://doi.org/10.1186/1940-0640-9-15.

    Article  Google Scholar 

  43. Knapp AA, Babbin SF, Budney AJ, Walker DD, Stephens RS, Scherer EA, Stanger C. Psychometric assessment of the marijuana adolescent problem inventory. Addict Behav. 2018;79(4):113–9.

    Article  Google Scholar 

  44. Lee CM, Neighbors C, Kilmer JR, Larimer ME. A brief, web-based personalized feedback selective intervention for college student marijuana use: a randomized clinical trial. Psychol Addict Behav. 2010;24(2):265–73. https://doi.org/10.1037/a0018859.

    Article  Google Scholar 

  45. Lee DC, Schlienz NJ, Peters EN, Dworkin RH, Turk DC, Strain EC, Vandrey R. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Drug Alcohol Depend. 2019;194:500–17. https://doi.org/10.1016/j.drugalcdep.2018.10.020.

    Article  Google Scholar 

  46. Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60. https://doi.org/10.1016/j.drugalcdep.2015.11.025.

    Article  CAS  Google Scholar 

  47. Marsch LA, Borodovsky JT. Technology-based interventions for preventing and treating substance use among youth. Child Adolesc Psychiatry Clin N Am. 2016;25(4):755–68. https://doi.org/10.1016/j.chc.2016.06.005.

    Article  Google Scholar 

  48. Marsch LA, Carroll KM, Kiluk BD. Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. J Subst Abus Treat. 2014;46(1):1–4. https://doi.org/10.1016/j.jsat.2013.08.010.

    Article  Google Scholar 

  49. Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abus Treat. 2008;34(4):407–14. doi: S0740-5472(07)00190-0 [pii] https://doi.org/10.1016/j.jsat.2007.07.004.

    Article  Google Scholar 

  50. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689–98. https://doi.org/10.1038/npp.2012.14.

    Article  CAS  Google Scholar 

  51. McCambridge J, Slym RL, Strang J. Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users. Addiction. 2008;103(11):1809–18. https://doi.org/10.1111/j.1360-0443.2008.02331.x.

    Article  Google Scholar 

  52. Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2019;(1):CD008940. https://doi.org/10.1002/14651858.CD008940.pub3.

  53. Parmar A, Sarkar S. Brief interventions for cannabis use disorders: a review. Addict Disord Treat. 2017;16(2):80–93. https://doi.org/10.1097/ADT.0000000000000100.

    Article  Google Scholar 

  54. Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903–14. https://doi.org/10.1016/j.jaac.2011.06.010.

    Article  Google Scholar 

  55. Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2019;9:1969. https://doi.org/10.3389/fpls.2018.01969.

    Article  Google Scholar 

  56. SAMHSA. Results from the 2016 National Survey on Drug Use and Health: summary of national findings. Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2017.

    Google Scholar 

  57. SAMHSA. Treatment episode data set. In 2015 SPSS Data. 2017. Retrieved from https://wwwdasis.samhsa.gov/dasis2/teds.htm.

  58. SAMHSA. Treatment episode data set (TEDS): 2005-2015. National admissions to substance abuse treatment services. BHSIS series S-91, HHS publication no. (SMA) 17-5037 (BHSIS series S-71, HHS publication no. (SMA) 14-4850). Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2017. Website: http://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.

  59. SAMHSA. Results from the 2017 National Survey on Drug Use and Health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2018.

    Google Scholar 

  60. Schaub MP, Wenger A, Berg O, Beck T, Stark L, Buehler E, Haug S. A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial. J Med Internet Res. 2015;17(10):e232. https://doi.org/10.2196/jmir.4860.

    Article  Google Scholar 

  61. Schlienz NJ, Lee DC, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018;187:254–60. https://doi.org/10.1016/j.drugalcdep.2018.02.022.

    Article  CAS  Google Scholar 

  62. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy. 2016;36(5):511–35. https://doi.org/10.1002/phar.1747.

    Article  Google Scholar 

  63. Shrier LA, Rhoads A, Burke P, Walls C, Blood EA. Real-time, contextual intervention using mobile technology to reduce marijuana use among youth: a pilot study. Addict Behav. 2014;39(1):173–80. https://doi.org/10.1016/j.addbeh.2013.09.028.

    Article  Google Scholar 

  64. Stanger C, Lansing AH, Budney AJ. Advances in research on contingency management for adolescent substance use. Child Adolesc Psychiatry Clin N Am. 2016;25(4):645–59. https://doi.org/10.1016/j.chc.2016.05.002.

    Article  Google Scholar 

  65. Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic- and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2015;54(6):445–53. e442. https://doi.org/10.1016/j.jaac.2015.02.009.

    Article  Google Scholar 

  66. Stephens RS, Babor TF, Kadden R, Miller M. The marijuana treatment project: rationale, design, and participant characteristics. Addiction. 2002;97(S1):109–24.

    Article  Google Scholar 

  67. Tanner-Smith EE, Wilson SJ, Lipsey MW. The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. J Subst Abus Treat. 2013;44(2):145–58. https://doi.org/10.1016/j.jsat.2012.05.006.

    Article  Google Scholar 

  68. UNODC. World drug report: pre-briefing to the member states. Vienna: United Nations Office on Drugs and Crime; 2018.

    Google Scholar 

  69. UNODC. World drug report 2019. Vienna: United Nations Office on Drugs and Crime; 2019.

    Google Scholar 

  70. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend. 2013;133(2):776–80. https://doi.org/10.1016/j.drugalcdep.2013.08.011.

    Article  Google Scholar 

  71. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117(1):38–44. https://doi.org/10.1016/j.drugalcdep.2011.01.003.

    Article  CAS  Google Scholar 

  72. Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported medical and nonmedical cannabis use among pregnant women in the United States medical and nonmedical cannabis use among pregnant women in the United States letters. JAMA. 2019;322(2):167–9. https://doi.org/10.1001/jama.2019.7982.

    Article  Google Scholar 

  73. Walker DD, Stephens RS, Blevins CE, Banes KE, Matthews L, Roffman RA. Augmenting brief interventions for adolescent marijuana users: the impact of motivational check-ins. J Consult Clin Psychol. 2016;84(11):983–92. https://doi.org/10.1037/ccp0000094.

    Article  Google Scholar 

  74. WHO. The health and social effects of nonmedical cannabis use. Geneva: World Health Organization; 2016.

    Google Scholar 

  75. Winters KC, Lee S, Botzet A, Fahnhorst T, Nicholson A. One-year outcomes and mediators of a brief intervention for drug abusing adolescents. Psychol Addict Behav. 2014;28(2):464–74. https://doi.org/10.1037/a0035041.

    Article  Google Scholar 

  76. Winters KC, Tanner-Smith EE, Bresani E, Meyers K. Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther. 2014;5:199–210. https://doi.org/10.2147/AHMT.S48053.

    Article  Google Scholar 

  77. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.

    Google Scholar 

  78. Zehra A, Burns J, Kure Liu C, Manza P, Wiers C, Volkow N, Wang G. Cannabis addiction and the brain: a review. J Neuroimmune Pharmacol. 2018;13:1–15. https://doi.org/10.1007/s11481-018-9782-9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Technology and Behavioral Health, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

    Alan J. Budney & Michael J. Sofis

Authors
  1. Alan J. Budney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Sofis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan J. Budney .

Editor information

Editors and Affiliations

  1. Division of Addiction Department of Psychiatry, University of Calgary, Calgary, AB, Canada

    Nady el-Guebaly

  2. Mental Health Department, University of Milano-Bicocca, Monza, Monza e Brianza, Italy

    Giuseppe Carrà

  3. Division of Alcoholism and Drug Abuse Department of Psychiatry, NYU School of Medicine, New York, NY, USA

    Marc Galanter

  4. Population and Behavioural Science Division (Psychiatry and Addictions), University of St Andrews, St.Andrews, UK

    Alexander M. Baldacchino

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Budney, A.J., Sofis, M.J. (2021). Cannabis Use Disorder and Its Treatment. In: el-Guebaly, N., Carrà, G., Galanter, M., Baldacchino, A.M. (eds) Textbook of Addiction Treatment. Springer, Cham. https://doi.org/10.1007/978-3-030-36391-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36391-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36390-1

  • Online ISBN: 978-3-030-36391-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation